Eli Lilly won a ruling in a lawsuit brought by Amylin Pharmaceuticals, Inc. The latter company sought to prevent Lilly from using the same sales force to sell Amylin's diabetes drug and that of a
competitor. A federal judge in San Diego denied Amylin's request for a preliminary order that would have imposed restrictions on Lilly's diabetes sales force, the Indianapolis-based drugmaker said in
a statement today. Amylin said Lilly's plans for marketing Boehringer Ingelheim GmbH's type 2 diabetes drug breached its agreement to develop and commercialize Amylin's competing drugs. Amylin said in
a statement today it will pursue the litigation.
Read the whole story at Bloomberg »
